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INTRODUCTION
The tumors that most commonly metastasize to
the adrenal gland are lung cancer, breast cancer,
gastric cancer, renal cell carcinoma, malignant
melanoma, followed by liver cancer (1, 2). Patients
may rarely present with solitary adrenal metas-
tasis (2). In general, the presence of adrenal me-
tastasis in endometrial adenocarcinoma indicates
widespread disease (3). Solitary adrenal metastasis
from endometrial adenocarcinoma is thus extremely
rare. To the best of our knowledge, only two cases
of isolated adrenal metastasis from endometrial ade-
nocarcinoma have been reported (3), and this rep-
resents the first description of a laparoscopically re-
sected solitary adrenal metastasis originating from
endometrial adenocarcinoma.
CASE REPORT
A 55-year-old woman presented in June 2004
with abnormal genital bleeding. She was referred
to our hospital with endometrial adenocarcinoma
in July 2004. Her serum carcinoembryonic antigen,
CA19-9 and CA125 were within normal limits. The
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patient underwent total abdominal hysterectomy
with bilateral salpingo- oophorectomy and pelvic
lymph node dissection. Histopathological exami-
nation revealed well-differentiated endometrial car-
cinoma with depth of myometraial invasion in the
inner one-half, with no invasion of the cervix or
adnexa. The cytological diagnosis of ascitis in the
pelvic cavity was negative, but she had pelvic node
involvement. We diagnosed stage IIIc. The patient
then received 7 courses of adjuvant chemotherapy
with carboplatin and paclitaxel. However, surveil-
lance computed tomography (CT) performed 14
months postoperatively revealed a suspicious right
adrenal tumor, 30 mm in diameter (Fig. 1), which
had not been present in previous scans. No other
sites of metastatic disease were identified. CT per-
formed 1 month later showed a rapidly enlarging
adrenal tumor, 57 mm in diameter, indicating me-
tastasis (Fig. 2). Laparoscopic adrenalectomy was
performed. Mild adhesions existed between the tu-
mor and liver or inferior vena cava, but the tumor
could be successfully removed. Operative time was
3 h 50 min. Pathological examination was consis-
tent with metastasis from the endometrial adeno-
carcinoma (Fig. 3). The patient was treated with 3
courses of adjuvant chemotherapy using carboplatin
and paclitaxel after laparoscopic adrenalectomy. She
has now been in good health without recurrence
for 5 years and 7 months after laparoscopic surgery.
DISCUSSION
Since the first report by Gagner et al. in 1991
(4), laparoscopic adrenalectomy has been adopted
as the gold standard for surgical management of
most adrenal tumors. Current indications for laparo-
scopic adrenalectomy include biochemically and
clinically functional adrenal tumors and potentially
malignant tumors of the adrenal gland (5). This in-
dication applies to the open adrenalectomy. Poten-
tially malignant tumors of the adrenal gland are gen-
erally considered to be non-functional tumors ex-
ceeding 5-6 cm in maximum diameter, including
Fig. 2 : CT showing rapid enlargement of the metastatic ad-
renal tumor, reaching 57 mm in diameter 15 months postopera-
tively.
Fig. 1 : Surveillance computed tomography performed 14
months postoperatively, revealing a right adrenal tumor, 30 mm in
diameter Fig. 3 : Histological appearance of metastatic adenocarcinoma(right) with compressed adrenal gland (left). The tumor displayed
glandular and solid patterns with necrosis, compatible with en-
dometrial adenocarcinoma. Bar, 40 μm.
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adrenal metastasis or primary adrenocortical carci-
noma. However, the role of laparoscopy in the treat-
ment of adrenal malignancies remain controversial.
In general, malignant tumor has the presence of
dense adhesions, fixation of the tumor, and unusu-
ally numerous retroperitoneal feeding vessels. In
this sense, the laparoscopic adrenalectomy for ad-
renal metastasis should be performed by expert la-
paroscopists (6). Laparoscopic adrenalectomy has
been contraindicated in cases of proven or suspected
primary adrenal cancer. The locoregional recurrence
rate after laparoscopic adrenalectomy of primary
adrenal cancer is 60%, occurring 1-2.5 years after
resection. This recurrence rate resembles that for
patients who have undergone open adrenalectomy
for adrenocortical carcinoma (7). As for metastatic
cancer, the presence of adrenal metastasis signals
widespread disease. In general, the prognosis of
patients with metastatic disease is poor, with few
survivors at 5 years. In regard to non-small cell lung
cancer, Luketich and Burt reported on 14 patients
with isolated adrenal metastasis from lung cancer.
Median survival was greater in the open surgical
resection plus chemotherapy group of 6 patients
(31 months) than in the chemotherapy alone group
of 6 patients (8.5 months, p=0.03) (8). The treat-
ment of isolated adrenal metastases mainly from
primary lung cancer is advantageous to the patient
if complete removal of the gland can be achieved
(9, 10), whereas chemotherapy alone thus seems to
have been largely ineffective against adrenal me-
tastasis from non-small cell lung cancer. The same
may apply to adrenal metastasis of endometrial ade-
nocarcinoma. In general, the presence of adrenal
metastasis from endometrial adenocarcinoma sig-
nals widespread or end-stage disease (3). Only 6%
of patients with recurrent uterus cancer survived 3
or more years (11). A solitary adrenal metastasis
from endometrial adenocarcinoma is extremely rare
(Table 1). Combination therapy with carboplatin and
paclitaxel reportedly covers the major effective drug
classes in the treatment of advanced and recurrent
endometrial cancer (12-14). Overall response rates
for patients with evaluable disease range from 62.0
to 82.1% (12 - 14). Our case was treated with 7
courses of adjuvant chemotherapy using carboplatin
and paclitaxel after the initial operation, but sur-
veillance CT performed 14 months postoperatively
revealed the right adrenal tumor, 30 mm in diame-
ter. CT 1 month later showed the adrenal tumor had
grown to 57 mm in diameter. The volume-doubling
time as calculated using the method originally de-
scribed by Schwartz (15) was 13 days. We diag-
nosed this rapidly enlarging adrenal tumor as adre-
nal metastasis from endometrial adenocarcinoma.
Chemotherapy thus seems to have been largely in-
effective against adrenal metastasis from the en-
dometrial adenocarcinoma. We therefore strongly
recommend performing additional surveillance CT
soon after detecting small adrenal tumor if the pri-
mary lesion was endometrial adenocarcinoma. In
addition, surgery should be performed as soon as
possible if the adrenal tumor is diagnosed as soli-
tary metastasis of endometrial adenocarcinoma.
Diagnosis of the adrenal tumor as a solitary ad-
renal metastasis is very important. Several reports
have described long-term survival after adrenalec-
tomy for isolated adrenal metastases. The devel-
opment of 18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) as an imaging tech-
nique utilizing the fact that malignant cells contain
increased levels of hexokinase (the enzyme respon-
sible for glucose phosphorylation) appears promis-
ing for characterizing metastatic adrenal masses.
The sensitivity, specificity, accuracy, positive pre-
dictive value, and negative predictive value of PET
and/or PET/CT in detecting recurrences in patients
with endometrial adenocarcinoma have been re-
ported as 100, 83.3, 96, 95, and 100%, respectively
(16). As we treated this patient before our hospi-
tal started running PET/CT, this modality was un-
available. Currently, all patients with confirmed or
Table 1 : Solitary adrenal metastasis cases from endometrial adenocarcinoma
No Age Tumorsize(mm)
Management of
primary tumor
Management of
adrenal tumor status
Survival
(months)
1 76 50 LaparotomyRadiation
Laparotomy
chemotherapy died 15
2 61 50 LaparotomyRadiation
Laparotomy
chemotherapy died 12
3 55 57 Laparotomychemotherapy
Laparotomy
chemotherapy alive 67
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suspected solitary adrenal metastasis at our insti-
tution undergo PET with the aim of confirming the
lesion as a solitary metastasis.
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